A randomized phase 3 trial of sofosbuvir/velpatasvir/ voxilaprevir for 8 weeks compared to sofosbuvir/ velpatasvir for 12 weeks in DAA-naïve genotype 1-6 HCV-infected patients: The POLARIS-2 study

Authors
Category Primary study
JournalHepatology
Year 2016
This article has no abstract
Epistemonikos ID: 99c6d0782e769b96e4810de3ad4bd23b85e108af
First added on: Feb 08, 2025